Industry representatives have voiced their support for the Biotech Act, hoping it will improve financing and institutional support of IVD makers.

Representing significant positions in more than one of Ark Invest's exchange-traded funds (ETFs), Tempus AI is ending the ...

The U.S. FDA issued a pair of final guidances this week, including one that outlines the criteria for authorizing emergency ...

One major change introduced by the EU MDR compared to the former European directives is the inclusion of products without an ...

Quality Control Market Size is projected to grow at a CAGR of 6.66% from 2024 to 2031, according to a new report published by Verified Market Research®. The report reveals that the market was valued ...

IVD devices enable earlier breast cancer diagnoses than mammograms, and detect genetic abnormalities that can contribute to ...

Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They ...

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, ...

U.S.-based Tempus AI (TEM) stock is up in early trading on Monday. Yesterday, the company received FDA clearance for its ...

Sensome CTO/COO Gor Lebedev says his company's big bet on a tiny chip yielded useful insights for other medical device ...

Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration ...